Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Actinogen Medical (ACW)

Latest price

AUD0.02

— 0.00 (−4.55)

As at 20/05/2025

Market capitalisation: AUD67m

View equity

edison tv

Healthcare

10.04.25

Actinogen Medical – equity proposition

Update

Healthcare

13.02.25

Actinogen Medical — XanaMIA Phase IIb/III study marches on

edison tv

Healthcare

24.01.25

NZD2.58

▾ −0.06 (−2.27)

As at 20/05/2025

Market capitalisation: NZD271m

View equity

Update

Healthcare

29.11.24

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

Flash note

Healthcare

04.11.24

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

Flash note

Healthcare

30.09.24

AUD0.12

▾ −0.01 (−4.17)

As at 20/05/2025

Market capitalisation: AUD9m

View equity

Update

Healthcare

14.10.24

Argent Biopharma — Valuation report

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

CHF44.75

▾ 0.25 (0.56)

As at 20/05/2025

Market capitalisation: CHF587m

View equity

Flash

Healthcare

19.02.25

Basilea Pharmaceutica — Another year, another market beat

Flash

Healthcare

06.02.25

Basilea Pharmaceutica — Encouraging start to the year for Cresemba

Flash note

Healthcare

17.12.24

USD1.51

▾ −0.01 (−0.66)

As at 20/05/2025

Market capitalisation: USD57m

View equity

Non client QV

Healthcare

29.01.25

SEK1.54

▾ 0.01 (0.79)

As at 20/05/2025

Market capitalisation: SEK382m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK11.74

▾ 0.64 (5.77)

As at 20/05/2025

Market capitalisation: SEK3,299m

View equity

Flash

Healthcare

23.04.25

Cereno Scientific — CS1 takes another step towards Phase IIb

Flash

Healthcare

17.04.25

Cereno Scientific — CS014 completes Phase I, path clears for Phase II

Update

Healthcare

17.03.25

SEK0.83

▾ 0.03 (3.13)

As at 20/05/2025

Market capitalisation: SEK59m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.10

▾ 0.13 (1.25)

As at 20/05/2025

Market capitalisation: GBP42m

View equity

edison tv

Healthcare

13.03.25

Creo Medical – executive interview

Update

Healthcare

03.03.25

Creo Medical — Refreshed business outlook

Flash

Healthcare

13.02.25

SEK5.45

— 0.00 (0.00)

As at 20/05/2025

Market capitalisation: SEK265m

View equity

Non client QV

Healthcare

26.02.25

EUR1.42

▾ −0.02 (−1.05)

As at 20/05/2025

Market capitalisation: EUR35m

View equity

edison tv

Healthcare

30.04.25

Herantis Pharma – executive interview

Non client QV

Healthcare

20.01.25

USD2.11

▾ 0.05 (2.43)

As at 20/05/2025

Market capitalisation: USD59m

View equity

Update

Healthcare

19.05.25

Immix Biopharma — Steady progress in Q125

Update

Healthcare

04.04.25

Immix Biopharma — All eyes on NEXICART-2

Flash

Healthcare

13.02.25

SEK7.21

▾ −0.09 (−1.23)

As at 20/05/2025

Market capitalisation: SEK379m

View equity

Flash

Healthcare

27.03.25

IRLAB Therapeutics — Next steps laid out for IRL757

Update

Healthcare

06.03.25

IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study

Flash

Healthcare

20.02.25

EUR0.13

▾ −0.05 (−27.57)

As at 20/05/2025

Market capitalisation: EUR2m

View equity

edison tv

Healthcare

29.10.24

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

edison tv

Healthcare

30.09.24

SEK5.20

▾ −0.19 (−3.53)

As at 20/05/2025

Market capitalisation: SEK272m

View equity

edison tv

Healthcare

16.05.25

Mendus – executive interview

Update

Healthcare

07.05.25

Mendus — No surprises in Q125 update

Flash

Healthcare

06.05.25

CHF7.77

▾ −0.10 (−1.27)

As at 20/05/2025

Market capitalisation: CHF141m

View equity

Flash

Healthcare

13.05.25

Newron Pharmaceuticals — Next stage unlocked for evenamide

Update

Healthcare

03.04.25

Newron Pharmaceuticals — Pivotal evenamide trial looms

Update

Healthcare

17.01.25

Newron Pharmaceuticals — Spotlight on evenamide following licensing deals

See more
content on

Newron Pharmaceuticals

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Mendus – executive interview

Isofol Medical – executive interview

The Diverse Income Trust – equity proposition

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.02

Actinogen Medical – equity proposition

Actinogen Medical — XanaMIA Phase IIb/III study marches on

Actinogen Medical – executive interview

See morecontent on

AFT Pharmaceuticals (AFT)

NZD2.58

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

See morecontent on

Argent Biopharma (RGT)

AUD0.12

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF44.75

Basilea Pharmaceutica — Another year, another market beat

Basilea Pharmaceutica — Encouraging start to the year for Cresemba

Basilea Pharmaceutica — Partner in place for US commercialisation of Zevtera

See morecontent on

Biomea Fusion (BMEA)

USD1.51

Biomea Fusion — An innovative approach to diabetes and obesity

See morecontent on

Cantargia (CANTA)

SEK1.54

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK11.74

Cereno Scientific — CS1 takes another step towards Phase IIb

Cereno Scientific — CS014 completes Phase I, path clears for Phase II

Cereno Scientific — Poised for active year in CVD and rare diseases

See morecontent on

Chosa (CHOSA)

SEK0.83

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.10

Creo Medical – executive interview

Creo Medical — Refreshed business outlook

Creo Medical — Consumables business divestment concludes

See morecontent on

Elicera Therapeutics (ELIC)

SEK5.45

Elicera Therapeutics — Positioned to deliver in cell and gene therapies

See morecontent on

Herantis Pharma (HRTIS)

EUR1.42

Herantis Pharma – executive interview

Herantis Pharma — Potential disease-modifier for PD

See morecontent on

Immix Biopharma (IMMX)

USD2.11

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on